One Postdoctoral position (Helse Sør-Øst) is available for 3 years, from September 1st 2019, in the Translational Research & Immunomonitoring Group at the Department of Cellular Therapy (PI: Dr. Sébastien Wälchli), Oslo University Hospital (OUS), Radiumhospitalet. Our focus is the development of new immunotherapy treatments against cancer. This includes the pre-clinical and clinical development and testing of enhanced cancer vaccines, adoptive T-cell therapy (TCR, CAR) and the improvement of cellular therapy for increased resistance to the microenvironment. After more than four years of activity, our results have already generated numerous patent applications, scientific publications, the establishment of a biotech company (Zelluna Immunotherapy AS) and the launching of a clinical protocol of T-cell therapy (NCT03431311).
Questions about the position can be sent to the following e-mail address: firstname.lastname@example.org.
Pre-clinical development of Chimeric Antigen Receptors (CARs) to treat solid tumours. During the past 4 years, we have established a unique CAR platform in Norway and Scandinavia, which can independently deliver CAR molecules starting from the antibody identification to the preclinical validations.
The candidate will (i) incorporate a team to support the finalization of an osteosarcoma-specific CAR (OSCAR) and (ii) prepare new solid tumour CARs designed from our hospital collection of hybridoma.
He/she will integrate a translational research group where all resources to perform experiments are in place. The team can operate independently from the molecular isolation of the sequences, the design of the therapeutic molecules, the cellular immunology work and the different phases of product assessment up to in vivo testing.
We have now acquired a strong experience on CAR and TCR development.
The candidate should full fill all the following criteria:
1: PhD or other corresponding education equivalent to a Norwegian doctoral degree.
2: We are exclusively seeking candidates with a Molecular Biology and biotechnology background orientated in immunology/immunotherapy. Application will not be considered if the candidate is unable to document via prior publications that he/she has designed, cloned and studied a synthetic immuno-molecule (antibody, TCR, CAR or another type of therapeutic receptors).
3: Strong level in Immunology required.
The candidate should possess at least one of these qualifications (to be documented via certificate or scientific publications):
1: A valid certification for animal experimentation (FELASA C), experience in protein expression/purification in any system or a good command in Flow cytometry.
2: A good command of English and informatics tools are expected and ability to independently write scientific articles will be required.
3: It will be considered as an advantage to have prior experience with: manipulation of different viral vectors (retro- or lenti-), cellular immunology, immunotherapy (CAR T-cells, TCR redirected T-cells), general knowledge in drug development, xenograft models or anti-tumor cellular immune response studies.
The application through webcruiter is obligatory and will not be considered if not sent as follows:
- Application letter (1 page) containing the requested information concerning the former experience (pts 2 and 4)
- CV (1 page max, summarizing education, positions, experience and other qualifying activities)
- Copies and transcripts of educational certificates
- A complete list of publications and unpublished works (submitted and in preparation with tracking numbers)
- Names and contact details of (min 1, max 3) references (name, relation to candidate, e-mail and telephone number)
- Only highly motivated candidates should apply for this position.
- The candidate should be able to work independently and develop his/her own projects, but is also expected to be a strong team player and actively participate to the general efforts of progression of the laboratory.
We offer a position in a dynamic environment within a modern (2015) and fully equipped facility. The project is oriented towards translational research, and the candidate will therefore be in contact with clinicians and have an access to clinical activities. Due to our location at the Oslo Cancer Cluster Incubator (occincubator.com), we are also directly in contact with industries and pharmaceutical companies. In addition the candidate will be encouraged to participate in at least one international conference per year where he/she will present his/her data.